So who’s more important: the drug users or the drug dealers?

28 Comments

Following up on the whole discipline angle from the last post, it definitely seems like more is going to happen before there is either any legal action or baseball disciplinary action in the A-Rod case. I mean, last I checked we don’t prosecute people based on newspaper articles alone.

But what that next step is will be extremely interesting. Because it will tell us whether Major League Baseball and the DEA is more interested in drug users or drug dealers.

Back in the Mitchell Report days, MLB, George Mitchell and federal agents went to the drug dealers first and gave them various degrees of immunity. Why? Because no one cared about drug dealers. The Mitchell Report, as I wrote at length back in the day, was a public relations exercise and everyone involved wanted to get the names of PED-using players out in the open. The league wanted to look like it was taking action, George Mitchell wanted prestige and billable hours for his law firm and the feds wanted some big, celebrity heads on pikes.  This, by the way, is a lot of the reason why the lowest hanging fruit was picked back then and guys like A-Rod and Biogenesis went unmentioned.

But what now?  Once again we have MLB and the DEA pursuing PEDs. Based on the Miami New Times report, the next obvious move for law enforcement is to either get players like A-Rod, Nelson Cruz, Bartolo Colon, Gio Gonzalez and others in a room to talk about the clinic’s possibly illegal prescriptions or else to get the clinic’s operators in to talk about the users. That’s how the next phase of this has to go.

Will the DEA decide to pursue distributors or end users? Will MLB seek out the quickest means to get “just cause” suspension evidence on the players, or will it attempt to learn everything it can about what may very well be the biggest pipeline of drugs into its sport?

The choices that are made about all of this in the coming days will tell us a lot about the league’s and the feds’ priorities.

Phillies’ Bryce Harper to miss start of season after elbow surgery

Getty Images
2 Comments

PHILADELPHIA – Phillies slugger Bryce Harper will miss the start of the 2023 season after he had reconstructive right elbow surgery.

The operation was performed by Dr. Neal ElAttrache in Los Angeles.

Harper is expected to return to Philadelphia’s lineup as the designated hitter by the All-Star break. He could be back in right field by the end of the season, according to the team.

The 30-year-old Harper suffered a small ulnar collateral ligament tear in his elbow in April. He last played right field at Miami on April 16. He had a platelet-rich plasma injection in May and shifted to designated hitter.

Harper met Nov. 14 with ElAttrache, who determined the tear did not heal on its own, necessitating surgery.

Even with the elbow injury, Harper led the Phillies to their first World Series since 2009, where they lost in six games to Houston. He hit .349 with six homers and 13 RBIs in 17 postseason games.

In late June, Harper suffered a broken thumb when he was hit by a pitch and was sidelined for two months. The two-time NL MVP still hit .286 with 18 homers and 65 RBIs for the season.

Harper left Washington and signed a 13-year, $330 million contract with the Phillies in 2019. A seven-time All-Star, Harper has 285 career home runs.

With Harper out, the Phillies could use Nick Castellanos and Kyle Schwarber at designated hitter. J.T. Realmuto also could serve as the DH when he needs a break from his catching duties.